Clinical Trial Update: Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) [Phase 3]

View source ↗

Summary

This Phase 3 trial update covers pembrolizumab given before surgery and with post-surgical radiotherapy for advanced head and neck squamous cell carcinoma, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Head and Neck Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-20